临床研究protocol到哪里查?

2019-05-29 不详 网络

研究方案(protocol)对整个研究工作的顺利开展起着关键的作用。项目研究方案提供了一个整体的项目框架,包括研究目的、研究设计、研究对象、样本量估计、疗效指标和研究终点等,是课题由设想转化为实际行动的关键步骤。了解一个研究最好的方法,并不是看它最终发表的文章,而是研究它的protocol。如何检索到protocol呢?常用方法有两种,第一种是直接在文献中查看附件,大部分高分文章都会在文章附件中附

研究方案(protocol)对整个研究工作的顺利开展起着关键的作用。项目研究方案提供了一个整体的项目框架,包括研究目的、研究设计、研究对象、样本量估计、疗效指标和研究终点等,是课题由设想转化为实际行动的关键步骤。虽然,一个protocol内容很多,但是,确实是极其全面的。深入研究一份protocol,可能比学习一篇SCI文章收获更多。如何检索到protocol呢?常用方法有两种,第一种是直接在文献中查看附件,大部分高分文章都会在文章附件中附上protocol,如新英格兰,JAMA等期刊。第二种是在各种SCI网站中检索。今天向大家介绍的就是一个汇聚众多protocol的神奇的网站---Trials.https://trialsjournal.biomedcentral.com/它是BMC旗下的一个杂志网站,虽然这个杂志并不是专门收集protocol的,但是他们家最受广大临床研究者们青睐,所以上面汇聚的临床研究方案越来越多。同时这个网站还有一点深得民心:所有文章无需注册,免费下载!只要是他们家杂志发表的文章,都可以直接可以免费下载,太良心了,有木有!所以平时没事的时候就可以打开网站,看看最

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (11)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2123959, encodeId=cc55212395998, content=谢谢分享!!感谢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230327/cab5f63feab2407fbd209165d9d7351d/df2c235bef964c84befbe0d32982ef61.jpg, createdBy=56018607786, createdName=北京中医药大学黄柠, createdTime=Wed Apr 05 22:22:54 CST 2023, time=2023-04-05, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1079065, encodeId=d8c810e90653c, content=太好了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7fe66397525, createdName=ms5000001434530416, createdTime=Sat Dec 11 15:45:10 CST 2021, time=2021-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059951, encodeId=cd941059951e8, content=感谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211012/a89d2b71b51f4a90b2d748410e2cb11b/c6399e5c034c48ec84b4c4ee74cdb730.jpg, createdBy=2d605633565, createdName=ABM丨同行人, createdTime=Tue Oct 12 22:38:41 CST 2021, time=2021-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057945, encodeId=5927105e94594, content=有用!, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210121/3066131e88ca4c31a238db2bedac2f10/1d8e8a6a6c4c4256b2b4a24b6723d68a.jpg, createdBy=91092531490, createdName=滚滚兔🐰, createdTime=Tue Oct 05 20:22:40 CST 2021, time=2021-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009293, encodeId=7cfe10092934a, content=很有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210818/f231a91ff9a44490a4dc0827cb3cd529/bab81ae5cb574d86a16038dfef9ec9b2.jpg, createdBy=a2895576231, createdName=ms7000001176921033, createdTime=Wed Aug 18 22:49:34 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=968491, encodeId=5278968491ea, content=好棒!, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210817/23cddf8b4fd64eb993e1ce0dc039919a/a5d2416ef1744efb8a761e2b41df007f.jpg, createdBy=f9635507778, createdName=小火龙111, createdTime=Tue May 25 23:12:05 CST 2021, time=2021-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=964525, encodeId=342e964525ff, content=棒棒的, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77695497752, createdName=ms9000001277574351, createdTime=Tue May 11 10:27:11 CST 2021, time=2021-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886684, encodeId=ec0c886684c8, content=Olll不错,真不错,pr真不错,真不错,pr真不错,真不错,pr真不错,真不错,pr不错,真不错,pr真不错,真不错,pr真不错,真不错,pr真不错,真不错,pr, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56f95419677, createdName=ms6000001508429735, createdTime=Sat Sep 19 16:40:48 CST 2020, time=2020-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634919, encodeId=018f163491923, content=<a href='/topic/show?id=c23314e6733' target=_blank style='color:#2F92EE;'>#protocol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14767, encryptionId=c23314e6733, topicName=protocol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63bb22340010, createdName=12498561m39(暂无昵称), createdTime=Thu Jul 25 08:56:00 CST 2019, time=2019-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=368060, encodeId=6374368060bc, content=太赞了,正好需要。谢谢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Qcj5xDGnJV65Un4lcVlusibuX88f17amqeZ9LnSuGRGvHxcSs1fMUKxal3Xuvgt5Rt5AHSeqRCINtCFGZ5qCyEA/132, createdBy=d8f42576630, createdName=yangtongtong, createdTime=Thu Jun 20 13:24:20 CST 2019, time=2019-06-20, status=1, ipAttribution=)]
    2023-04-05 北京中医药大学黄柠 来自北京

    谢谢分享!!感谢!

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2123959, encodeId=cc55212395998, content=谢谢分享!!感谢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230327/cab5f63feab2407fbd209165d9d7351d/df2c235bef964c84befbe0d32982ef61.jpg, createdBy=56018607786, createdName=北京中医药大学黄柠, createdTime=Wed Apr 05 22:22:54 CST 2023, time=2023-04-05, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1079065, encodeId=d8c810e90653c, content=太好了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7fe66397525, createdName=ms5000001434530416, createdTime=Sat Dec 11 15:45:10 CST 2021, time=2021-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059951, encodeId=cd941059951e8, content=感谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211012/a89d2b71b51f4a90b2d748410e2cb11b/c6399e5c034c48ec84b4c4ee74cdb730.jpg, createdBy=2d605633565, createdName=ABM丨同行人, createdTime=Tue Oct 12 22:38:41 CST 2021, time=2021-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057945, encodeId=5927105e94594, content=有用!, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210121/3066131e88ca4c31a238db2bedac2f10/1d8e8a6a6c4c4256b2b4a24b6723d68a.jpg, createdBy=91092531490, createdName=滚滚兔🐰, createdTime=Tue Oct 05 20:22:40 CST 2021, time=2021-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009293, encodeId=7cfe10092934a, content=很有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210818/f231a91ff9a44490a4dc0827cb3cd529/bab81ae5cb574d86a16038dfef9ec9b2.jpg, createdBy=a2895576231, createdName=ms7000001176921033, createdTime=Wed Aug 18 22:49:34 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=968491, encodeId=5278968491ea, content=好棒!, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210817/23cddf8b4fd64eb993e1ce0dc039919a/a5d2416ef1744efb8a761e2b41df007f.jpg, createdBy=f9635507778, createdName=小火龙111, createdTime=Tue May 25 23:12:05 CST 2021, time=2021-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=964525, encodeId=342e964525ff, content=棒棒的, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77695497752, createdName=ms9000001277574351, createdTime=Tue May 11 10:27:11 CST 2021, time=2021-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886684, encodeId=ec0c886684c8, content=Olll不错,真不错,pr真不错,真不错,pr真不错,真不错,pr真不错,真不错,pr不错,真不错,pr真不错,真不错,pr真不错,真不错,pr真不错,真不错,pr, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56f95419677, createdName=ms6000001508429735, createdTime=Sat Sep 19 16:40:48 CST 2020, time=2020-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634919, encodeId=018f163491923, content=<a href='/topic/show?id=c23314e6733' target=_blank style='color:#2F92EE;'>#protocol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14767, encryptionId=c23314e6733, topicName=protocol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63bb22340010, createdName=12498561m39(暂无昵称), createdTime=Thu Jul 25 08:56:00 CST 2019, time=2019-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=368060, encodeId=6374368060bc, content=太赞了,正好需要。谢谢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Qcj5xDGnJV65Un4lcVlusibuX88f17amqeZ9LnSuGRGvHxcSs1fMUKxal3Xuvgt5Rt5AHSeqRCINtCFGZ5qCyEA/132, createdBy=d8f42576630, createdName=yangtongtong, createdTime=Thu Jun 20 13:24:20 CST 2019, time=2019-06-20, status=1, ipAttribution=)]
    2021-12-11 ms5000001434530416

    太好了!

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2123959, encodeId=cc55212395998, content=谢谢分享!!感谢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230327/cab5f63feab2407fbd209165d9d7351d/df2c235bef964c84befbe0d32982ef61.jpg, createdBy=56018607786, createdName=北京中医药大学黄柠, createdTime=Wed Apr 05 22:22:54 CST 2023, time=2023-04-05, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1079065, encodeId=d8c810e90653c, content=太好了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7fe66397525, createdName=ms5000001434530416, createdTime=Sat Dec 11 15:45:10 CST 2021, time=2021-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059951, encodeId=cd941059951e8, content=感谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211012/a89d2b71b51f4a90b2d748410e2cb11b/c6399e5c034c48ec84b4c4ee74cdb730.jpg, createdBy=2d605633565, createdName=ABM丨同行人, createdTime=Tue Oct 12 22:38:41 CST 2021, time=2021-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057945, encodeId=5927105e94594, content=有用!, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210121/3066131e88ca4c31a238db2bedac2f10/1d8e8a6a6c4c4256b2b4a24b6723d68a.jpg, createdBy=91092531490, createdName=滚滚兔🐰, createdTime=Tue Oct 05 20:22:40 CST 2021, time=2021-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009293, encodeId=7cfe10092934a, content=很有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210818/f231a91ff9a44490a4dc0827cb3cd529/bab81ae5cb574d86a16038dfef9ec9b2.jpg, createdBy=a2895576231, createdName=ms7000001176921033, createdTime=Wed Aug 18 22:49:34 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=968491, encodeId=5278968491ea, content=好棒!, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210817/23cddf8b4fd64eb993e1ce0dc039919a/a5d2416ef1744efb8a761e2b41df007f.jpg, createdBy=f9635507778, createdName=小火龙111, createdTime=Tue May 25 23:12:05 CST 2021, time=2021-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=964525, encodeId=342e964525ff, content=棒棒的, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77695497752, createdName=ms9000001277574351, createdTime=Tue May 11 10:27:11 CST 2021, time=2021-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886684, encodeId=ec0c886684c8, content=Olll不错,真不错,pr真不错,真不错,pr真不错,真不错,pr真不错,真不错,pr不错,真不错,pr真不错,真不错,pr真不错,真不错,pr真不错,真不错,pr, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56f95419677, createdName=ms6000001508429735, createdTime=Sat Sep 19 16:40:48 CST 2020, time=2020-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634919, encodeId=018f163491923, content=<a href='/topic/show?id=c23314e6733' target=_blank style='color:#2F92EE;'>#protocol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14767, encryptionId=c23314e6733, topicName=protocol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63bb22340010, createdName=12498561m39(暂无昵称), createdTime=Thu Jul 25 08:56:00 CST 2019, time=2019-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=368060, encodeId=6374368060bc, content=太赞了,正好需要。谢谢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Qcj5xDGnJV65Un4lcVlusibuX88f17amqeZ9LnSuGRGvHxcSs1fMUKxal3Xuvgt5Rt5AHSeqRCINtCFGZ5qCyEA/132, createdBy=d8f42576630, createdName=yangtongtong, createdTime=Thu Jun 20 13:24:20 CST 2019, time=2019-06-20, status=1, ipAttribution=)]
    2021-10-12 ABM丨同行人

    感谢分享!

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2123959, encodeId=cc55212395998, content=谢谢分享!!感谢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230327/cab5f63feab2407fbd209165d9d7351d/df2c235bef964c84befbe0d32982ef61.jpg, createdBy=56018607786, createdName=北京中医药大学黄柠, createdTime=Wed Apr 05 22:22:54 CST 2023, time=2023-04-05, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1079065, encodeId=d8c810e90653c, content=太好了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7fe66397525, createdName=ms5000001434530416, createdTime=Sat Dec 11 15:45:10 CST 2021, time=2021-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059951, encodeId=cd941059951e8, content=感谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211012/a89d2b71b51f4a90b2d748410e2cb11b/c6399e5c034c48ec84b4c4ee74cdb730.jpg, createdBy=2d605633565, createdName=ABM丨同行人, createdTime=Tue Oct 12 22:38:41 CST 2021, time=2021-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057945, encodeId=5927105e94594, content=有用!, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210121/3066131e88ca4c31a238db2bedac2f10/1d8e8a6a6c4c4256b2b4a24b6723d68a.jpg, createdBy=91092531490, createdName=滚滚兔🐰, createdTime=Tue Oct 05 20:22:40 CST 2021, time=2021-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009293, encodeId=7cfe10092934a, content=很有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210818/f231a91ff9a44490a4dc0827cb3cd529/bab81ae5cb574d86a16038dfef9ec9b2.jpg, createdBy=a2895576231, createdName=ms7000001176921033, createdTime=Wed Aug 18 22:49:34 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=968491, encodeId=5278968491ea, content=好棒!, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210817/23cddf8b4fd64eb993e1ce0dc039919a/a5d2416ef1744efb8a761e2b41df007f.jpg, createdBy=f9635507778, createdName=小火龙111, createdTime=Tue May 25 23:12:05 CST 2021, time=2021-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=964525, encodeId=342e964525ff, content=棒棒的, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77695497752, createdName=ms9000001277574351, createdTime=Tue May 11 10:27:11 CST 2021, time=2021-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886684, encodeId=ec0c886684c8, content=Olll不错,真不错,pr真不错,真不错,pr真不错,真不错,pr真不错,真不错,pr不错,真不错,pr真不错,真不错,pr真不错,真不错,pr真不错,真不错,pr, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56f95419677, createdName=ms6000001508429735, createdTime=Sat Sep 19 16:40:48 CST 2020, time=2020-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634919, encodeId=018f163491923, content=<a href='/topic/show?id=c23314e6733' target=_blank style='color:#2F92EE;'>#protocol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14767, encryptionId=c23314e6733, topicName=protocol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63bb22340010, createdName=12498561m39(暂无昵称), createdTime=Thu Jul 25 08:56:00 CST 2019, time=2019-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=368060, encodeId=6374368060bc, content=太赞了,正好需要。谢谢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Qcj5xDGnJV65Un4lcVlusibuX88f17amqeZ9LnSuGRGvHxcSs1fMUKxal3Xuvgt5Rt5AHSeqRCINtCFGZ5qCyEA/132, createdBy=d8f42576630, createdName=yangtongtong, createdTime=Thu Jun 20 13:24:20 CST 2019, time=2019-06-20, status=1, ipAttribution=)]
    2021-10-05 滚滚兔🐰

    有用!

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2123959, encodeId=cc55212395998, content=谢谢分享!!感谢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230327/cab5f63feab2407fbd209165d9d7351d/df2c235bef964c84befbe0d32982ef61.jpg, createdBy=56018607786, createdName=北京中医药大学黄柠, createdTime=Wed Apr 05 22:22:54 CST 2023, time=2023-04-05, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1079065, encodeId=d8c810e90653c, content=太好了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7fe66397525, createdName=ms5000001434530416, createdTime=Sat Dec 11 15:45:10 CST 2021, time=2021-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059951, encodeId=cd941059951e8, content=感谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211012/a89d2b71b51f4a90b2d748410e2cb11b/c6399e5c034c48ec84b4c4ee74cdb730.jpg, createdBy=2d605633565, createdName=ABM丨同行人, createdTime=Tue Oct 12 22:38:41 CST 2021, time=2021-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057945, encodeId=5927105e94594, content=有用!, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210121/3066131e88ca4c31a238db2bedac2f10/1d8e8a6a6c4c4256b2b4a24b6723d68a.jpg, createdBy=91092531490, createdName=滚滚兔🐰, createdTime=Tue Oct 05 20:22:40 CST 2021, time=2021-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009293, encodeId=7cfe10092934a, content=很有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210818/f231a91ff9a44490a4dc0827cb3cd529/bab81ae5cb574d86a16038dfef9ec9b2.jpg, createdBy=a2895576231, createdName=ms7000001176921033, createdTime=Wed Aug 18 22:49:34 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=968491, encodeId=5278968491ea, content=好棒!, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210817/23cddf8b4fd64eb993e1ce0dc039919a/a5d2416ef1744efb8a761e2b41df007f.jpg, createdBy=f9635507778, createdName=小火龙111, createdTime=Tue May 25 23:12:05 CST 2021, time=2021-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=964525, encodeId=342e964525ff, content=棒棒的, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77695497752, createdName=ms9000001277574351, createdTime=Tue May 11 10:27:11 CST 2021, time=2021-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886684, encodeId=ec0c886684c8, content=Olll不错,真不错,pr真不错,真不错,pr真不错,真不错,pr真不错,真不错,pr不错,真不错,pr真不错,真不错,pr真不错,真不错,pr真不错,真不错,pr, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56f95419677, createdName=ms6000001508429735, createdTime=Sat Sep 19 16:40:48 CST 2020, time=2020-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634919, encodeId=018f163491923, content=<a href='/topic/show?id=c23314e6733' target=_blank style='color:#2F92EE;'>#protocol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14767, encryptionId=c23314e6733, topicName=protocol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63bb22340010, createdName=12498561m39(暂无昵称), createdTime=Thu Jul 25 08:56:00 CST 2019, time=2019-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=368060, encodeId=6374368060bc, content=太赞了,正好需要。谢谢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Qcj5xDGnJV65Un4lcVlusibuX88f17amqeZ9LnSuGRGvHxcSs1fMUKxal3Xuvgt5Rt5AHSeqRCINtCFGZ5qCyEA/132, createdBy=d8f42576630, createdName=yangtongtong, createdTime=Thu Jun 20 13:24:20 CST 2019, time=2019-06-20, status=1, ipAttribution=)]
    2021-08-18 ms7000001176921033

    很有用

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2123959, encodeId=cc55212395998, content=谢谢分享!!感谢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230327/cab5f63feab2407fbd209165d9d7351d/df2c235bef964c84befbe0d32982ef61.jpg, createdBy=56018607786, createdName=北京中医药大学黄柠, createdTime=Wed Apr 05 22:22:54 CST 2023, time=2023-04-05, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1079065, encodeId=d8c810e90653c, content=太好了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7fe66397525, createdName=ms5000001434530416, createdTime=Sat Dec 11 15:45:10 CST 2021, time=2021-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059951, encodeId=cd941059951e8, content=感谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211012/a89d2b71b51f4a90b2d748410e2cb11b/c6399e5c034c48ec84b4c4ee74cdb730.jpg, createdBy=2d605633565, createdName=ABM丨同行人, createdTime=Tue Oct 12 22:38:41 CST 2021, time=2021-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057945, encodeId=5927105e94594, content=有用!, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210121/3066131e88ca4c31a238db2bedac2f10/1d8e8a6a6c4c4256b2b4a24b6723d68a.jpg, createdBy=91092531490, createdName=滚滚兔🐰, createdTime=Tue Oct 05 20:22:40 CST 2021, time=2021-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009293, encodeId=7cfe10092934a, content=很有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210818/f231a91ff9a44490a4dc0827cb3cd529/bab81ae5cb574d86a16038dfef9ec9b2.jpg, createdBy=a2895576231, createdName=ms7000001176921033, createdTime=Wed Aug 18 22:49:34 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=968491, encodeId=5278968491ea, content=好棒!, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210817/23cddf8b4fd64eb993e1ce0dc039919a/a5d2416ef1744efb8a761e2b41df007f.jpg, createdBy=f9635507778, createdName=小火龙111, createdTime=Tue May 25 23:12:05 CST 2021, time=2021-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=964525, encodeId=342e964525ff, content=棒棒的, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77695497752, createdName=ms9000001277574351, createdTime=Tue May 11 10:27:11 CST 2021, time=2021-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886684, encodeId=ec0c886684c8, content=Olll不错,真不错,pr真不错,真不错,pr真不错,真不错,pr真不错,真不错,pr不错,真不错,pr真不错,真不错,pr真不错,真不错,pr真不错,真不错,pr, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56f95419677, createdName=ms6000001508429735, createdTime=Sat Sep 19 16:40:48 CST 2020, time=2020-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634919, encodeId=018f163491923, content=<a href='/topic/show?id=c23314e6733' target=_blank style='color:#2F92EE;'>#protocol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14767, encryptionId=c23314e6733, topicName=protocol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63bb22340010, createdName=12498561m39(暂无昵称), createdTime=Thu Jul 25 08:56:00 CST 2019, time=2019-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=368060, encodeId=6374368060bc, content=太赞了,正好需要。谢谢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Qcj5xDGnJV65Un4lcVlusibuX88f17amqeZ9LnSuGRGvHxcSs1fMUKxal3Xuvgt5Rt5AHSeqRCINtCFGZ5qCyEA/132, createdBy=d8f42576630, createdName=yangtongtong, createdTime=Thu Jun 20 13:24:20 CST 2019, time=2019-06-20, status=1, ipAttribution=)]
    2021-05-25 小火龙111

    好棒!

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2123959, encodeId=cc55212395998, content=谢谢分享!!感谢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230327/cab5f63feab2407fbd209165d9d7351d/df2c235bef964c84befbe0d32982ef61.jpg, createdBy=56018607786, createdName=北京中医药大学黄柠, createdTime=Wed Apr 05 22:22:54 CST 2023, time=2023-04-05, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1079065, encodeId=d8c810e90653c, content=太好了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7fe66397525, createdName=ms5000001434530416, createdTime=Sat Dec 11 15:45:10 CST 2021, time=2021-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059951, encodeId=cd941059951e8, content=感谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211012/a89d2b71b51f4a90b2d748410e2cb11b/c6399e5c034c48ec84b4c4ee74cdb730.jpg, createdBy=2d605633565, createdName=ABM丨同行人, createdTime=Tue Oct 12 22:38:41 CST 2021, time=2021-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057945, encodeId=5927105e94594, content=有用!, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210121/3066131e88ca4c31a238db2bedac2f10/1d8e8a6a6c4c4256b2b4a24b6723d68a.jpg, createdBy=91092531490, createdName=滚滚兔🐰, createdTime=Tue Oct 05 20:22:40 CST 2021, time=2021-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009293, encodeId=7cfe10092934a, content=很有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210818/f231a91ff9a44490a4dc0827cb3cd529/bab81ae5cb574d86a16038dfef9ec9b2.jpg, createdBy=a2895576231, createdName=ms7000001176921033, createdTime=Wed Aug 18 22:49:34 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=968491, encodeId=5278968491ea, content=好棒!, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210817/23cddf8b4fd64eb993e1ce0dc039919a/a5d2416ef1744efb8a761e2b41df007f.jpg, createdBy=f9635507778, createdName=小火龙111, createdTime=Tue May 25 23:12:05 CST 2021, time=2021-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=964525, encodeId=342e964525ff, content=棒棒的, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77695497752, createdName=ms9000001277574351, createdTime=Tue May 11 10:27:11 CST 2021, time=2021-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886684, encodeId=ec0c886684c8, content=Olll不错,真不错,pr真不错,真不错,pr真不错,真不错,pr真不错,真不错,pr不错,真不错,pr真不错,真不错,pr真不错,真不错,pr真不错,真不错,pr, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56f95419677, createdName=ms6000001508429735, createdTime=Sat Sep 19 16:40:48 CST 2020, time=2020-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634919, encodeId=018f163491923, content=<a href='/topic/show?id=c23314e6733' target=_blank style='color:#2F92EE;'>#protocol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14767, encryptionId=c23314e6733, topicName=protocol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63bb22340010, createdName=12498561m39(暂无昵称), createdTime=Thu Jul 25 08:56:00 CST 2019, time=2019-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=368060, encodeId=6374368060bc, content=太赞了,正好需要。谢谢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Qcj5xDGnJV65Un4lcVlusibuX88f17amqeZ9LnSuGRGvHxcSs1fMUKxal3Xuvgt5Rt5AHSeqRCINtCFGZ5qCyEA/132, createdBy=d8f42576630, createdName=yangtongtong, createdTime=Thu Jun 20 13:24:20 CST 2019, time=2019-06-20, status=1, ipAttribution=)]
    2021-05-11 ms9000001277574351

    棒棒的

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=2123959, encodeId=cc55212395998, content=谢谢分享!!感谢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230327/cab5f63feab2407fbd209165d9d7351d/df2c235bef964c84befbe0d32982ef61.jpg, createdBy=56018607786, createdName=北京中医药大学黄柠, createdTime=Wed Apr 05 22:22:54 CST 2023, time=2023-04-05, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1079065, encodeId=d8c810e90653c, content=太好了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7fe66397525, createdName=ms5000001434530416, createdTime=Sat Dec 11 15:45:10 CST 2021, time=2021-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059951, encodeId=cd941059951e8, content=感谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211012/a89d2b71b51f4a90b2d748410e2cb11b/c6399e5c034c48ec84b4c4ee74cdb730.jpg, createdBy=2d605633565, createdName=ABM丨同行人, createdTime=Tue Oct 12 22:38:41 CST 2021, time=2021-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057945, encodeId=5927105e94594, content=有用!, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210121/3066131e88ca4c31a238db2bedac2f10/1d8e8a6a6c4c4256b2b4a24b6723d68a.jpg, createdBy=91092531490, createdName=滚滚兔🐰, createdTime=Tue Oct 05 20:22:40 CST 2021, time=2021-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009293, encodeId=7cfe10092934a, content=很有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210818/f231a91ff9a44490a4dc0827cb3cd529/bab81ae5cb574d86a16038dfef9ec9b2.jpg, createdBy=a2895576231, createdName=ms7000001176921033, createdTime=Wed Aug 18 22:49:34 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=968491, encodeId=5278968491ea, content=好棒!, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210817/23cddf8b4fd64eb993e1ce0dc039919a/a5d2416ef1744efb8a761e2b41df007f.jpg, createdBy=f9635507778, createdName=小火龙111, createdTime=Tue May 25 23:12:05 CST 2021, time=2021-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=964525, encodeId=342e964525ff, content=棒棒的, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77695497752, createdName=ms9000001277574351, createdTime=Tue May 11 10:27:11 CST 2021, time=2021-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886684, encodeId=ec0c886684c8, content=Olll不错,真不错,pr真不错,真不错,pr真不错,真不错,pr真不错,真不错,pr不错,真不错,pr真不错,真不错,pr真不错,真不错,pr真不错,真不错,pr, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56f95419677, createdName=ms6000001508429735, createdTime=Sat Sep 19 16:40:48 CST 2020, time=2020-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634919, encodeId=018f163491923, content=<a href='/topic/show?id=c23314e6733' target=_blank style='color:#2F92EE;'>#protocol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14767, encryptionId=c23314e6733, topicName=protocol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63bb22340010, createdName=12498561m39(暂无昵称), createdTime=Thu Jul 25 08:56:00 CST 2019, time=2019-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=368060, encodeId=6374368060bc, content=太赞了,正好需要。谢谢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Qcj5xDGnJV65Un4lcVlusibuX88f17amqeZ9LnSuGRGvHxcSs1fMUKxal3Xuvgt5Rt5AHSeqRCINtCFGZ5qCyEA/132, createdBy=d8f42576630, createdName=yangtongtong, createdTime=Thu Jun 20 13:24:20 CST 2019, time=2019-06-20, status=1, ipAttribution=)]
    2020-09-19 ms6000001508429735

    Olll不错,真不错,pr真不错,真不错,pr真不错,真不错,pr真不错,真不错,pr不错,真不错,pr真不错,真不错,pr真不错,真不错,pr真不错,真不错,pr

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=2123959, encodeId=cc55212395998, content=谢谢分享!!感谢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230327/cab5f63feab2407fbd209165d9d7351d/df2c235bef964c84befbe0d32982ef61.jpg, createdBy=56018607786, createdName=北京中医药大学黄柠, createdTime=Wed Apr 05 22:22:54 CST 2023, time=2023-04-05, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1079065, encodeId=d8c810e90653c, content=太好了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7fe66397525, createdName=ms5000001434530416, createdTime=Sat Dec 11 15:45:10 CST 2021, time=2021-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059951, encodeId=cd941059951e8, content=感谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211012/a89d2b71b51f4a90b2d748410e2cb11b/c6399e5c034c48ec84b4c4ee74cdb730.jpg, createdBy=2d605633565, createdName=ABM丨同行人, createdTime=Tue Oct 12 22:38:41 CST 2021, time=2021-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057945, encodeId=5927105e94594, content=有用!, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210121/3066131e88ca4c31a238db2bedac2f10/1d8e8a6a6c4c4256b2b4a24b6723d68a.jpg, createdBy=91092531490, createdName=滚滚兔🐰, createdTime=Tue Oct 05 20:22:40 CST 2021, time=2021-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009293, encodeId=7cfe10092934a, content=很有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210818/f231a91ff9a44490a4dc0827cb3cd529/bab81ae5cb574d86a16038dfef9ec9b2.jpg, createdBy=a2895576231, createdName=ms7000001176921033, createdTime=Wed Aug 18 22:49:34 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=968491, encodeId=5278968491ea, content=好棒!, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210817/23cddf8b4fd64eb993e1ce0dc039919a/a5d2416ef1744efb8a761e2b41df007f.jpg, createdBy=f9635507778, createdName=小火龙111, createdTime=Tue May 25 23:12:05 CST 2021, time=2021-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=964525, encodeId=342e964525ff, content=棒棒的, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77695497752, createdName=ms9000001277574351, createdTime=Tue May 11 10:27:11 CST 2021, time=2021-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886684, encodeId=ec0c886684c8, content=Olll不错,真不错,pr真不错,真不错,pr真不错,真不错,pr真不错,真不错,pr不错,真不错,pr真不错,真不错,pr真不错,真不错,pr真不错,真不错,pr, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56f95419677, createdName=ms6000001508429735, createdTime=Sat Sep 19 16:40:48 CST 2020, time=2020-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634919, encodeId=018f163491923, content=<a href='/topic/show?id=c23314e6733' target=_blank style='color:#2F92EE;'>#protocol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14767, encryptionId=c23314e6733, topicName=protocol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63bb22340010, createdName=12498561m39(暂无昵称), createdTime=Thu Jul 25 08:56:00 CST 2019, time=2019-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=368060, encodeId=6374368060bc, content=太赞了,正好需要。谢谢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Qcj5xDGnJV65Un4lcVlusibuX88f17amqeZ9LnSuGRGvHxcSs1fMUKxal3Xuvgt5Rt5AHSeqRCINtCFGZ5qCyEA/132, createdBy=d8f42576630, createdName=yangtongtong, createdTime=Thu Jun 20 13:24:20 CST 2019, time=2019-06-20, status=1, ipAttribution=)]
  10. [GetPortalCommentsPageByObjectIdResponse(id=2123959, encodeId=cc55212395998, content=谢谢分享!!感谢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230327/cab5f63feab2407fbd209165d9d7351d/df2c235bef964c84befbe0d32982ef61.jpg, createdBy=56018607786, createdName=北京中医药大学黄柠, createdTime=Wed Apr 05 22:22:54 CST 2023, time=2023-04-05, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1079065, encodeId=d8c810e90653c, content=太好了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7fe66397525, createdName=ms5000001434530416, createdTime=Sat Dec 11 15:45:10 CST 2021, time=2021-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059951, encodeId=cd941059951e8, content=感谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211012/a89d2b71b51f4a90b2d748410e2cb11b/c6399e5c034c48ec84b4c4ee74cdb730.jpg, createdBy=2d605633565, createdName=ABM丨同行人, createdTime=Tue Oct 12 22:38:41 CST 2021, time=2021-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057945, encodeId=5927105e94594, content=有用!, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210121/3066131e88ca4c31a238db2bedac2f10/1d8e8a6a6c4c4256b2b4a24b6723d68a.jpg, createdBy=91092531490, createdName=滚滚兔🐰, createdTime=Tue Oct 05 20:22:40 CST 2021, time=2021-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009293, encodeId=7cfe10092934a, content=很有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210818/f231a91ff9a44490a4dc0827cb3cd529/bab81ae5cb574d86a16038dfef9ec9b2.jpg, createdBy=a2895576231, createdName=ms7000001176921033, createdTime=Wed Aug 18 22:49:34 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=968491, encodeId=5278968491ea, content=好棒!, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210817/23cddf8b4fd64eb993e1ce0dc039919a/a5d2416ef1744efb8a761e2b41df007f.jpg, createdBy=f9635507778, createdName=小火龙111, createdTime=Tue May 25 23:12:05 CST 2021, time=2021-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=964525, encodeId=342e964525ff, content=棒棒的, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77695497752, createdName=ms9000001277574351, createdTime=Tue May 11 10:27:11 CST 2021, time=2021-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886684, encodeId=ec0c886684c8, content=Olll不错,真不错,pr真不错,真不错,pr真不错,真不错,pr真不错,真不错,pr不错,真不错,pr真不错,真不错,pr真不错,真不错,pr真不错,真不错,pr, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56f95419677, createdName=ms6000001508429735, createdTime=Sat Sep 19 16:40:48 CST 2020, time=2020-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634919, encodeId=018f163491923, content=<a href='/topic/show?id=c23314e6733' target=_blank style='color:#2F92EE;'>#protocol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14767, encryptionId=c23314e6733, topicName=protocol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63bb22340010, createdName=12498561m39(暂无昵称), createdTime=Thu Jul 25 08:56:00 CST 2019, time=2019-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=368060, encodeId=6374368060bc, content=太赞了,正好需要。谢谢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Qcj5xDGnJV65Un4lcVlusibuX88f17amqeZ9LnSuGRGvHxcSs1fMUKxal3Xuvgt5Rt5AHSeqRCINtCFGZ5qCyEA/132, createdBy=d8f42576630, createdName=yangtongtong, createdTime=Thu Jun 20 13:24:20 CST 2019, time=2019-06-20, status=1, ipAttribution=)]
    2019-06-20 yangtongtong

    太赞了,正好需要。谢谢!

    0

相关资讯

“共享阳光——重大疾病临床科研合作项目”启动:提升临床研究能力,培养中青年学科人才

2019年4月17日,由白求恩公益基金会发起,赛诺菲中国支持的“共享阳光——重大疾病临床科研合作项目”(以下简称“共享阳光”项目)在北京正式启动。该项目旨在提升我国中青年临床专家在实体肿瘤、血液疾病、器官移植及神经科学等重大疾病领域的科学研究能力,推动学科创新和人才培养,助力“健康中国”战略建设。“共享阳光——重大疾病临床科研合作项目”启动在我国,肿瘤、血液疾病、实体器官移植及神经学领域等致死性或

The BMJ:临床研究结果先公之于众?还是先同行评议?

2018年11月23日,诺和诺德(Novo Nordisk)公司发布了一份500字的新闻稿,报道PIONEER 6 [口服胰高血糖素样肽1(GLP-1)的类似物——索马鲁肽(semaglutide)的心血管结果试验]的结果。我们认为这项研究将很快就会在一份同行评议的期刊上发表,但与此同时,该新闻报道称“该药物可使心血管死亡和全因死亡率均显着下降”。因为美国食品与药品监督管理局(FDA)在2017年

临床研究中的盲法:难 OR 不难?

信息偏倚是医学研究中常见的,偏倚既可以来自研究人员,也可以来自研究对象(受试者)。如果研究对象知道自己在对照组,则可能因主观因素而反映出较差的疗效;另一方面,如果研究人员知道受试者的分组情况,出于对阳性结论的期望将诱导治疗组产生有利结果。为了尽可能减少来自研究者或受试者主观因素导致的信息偏倚,我们在医学类科研中需要用到“盲法”。 什么叫“盲法” 所谓“盲法”(blinding或masking)

好的临床研究应该什么样?——王拥军告诉你书上没有的经验

王拥军教授在临床科研方面走得顺风顺水,他带领团队进行“国家卒中登记研究”,至今该数据库已产出80多篇SCI论文,并连续四年成为《Stroke》杂志单中心发表文章数量冠军。他们完成的CHANCE研究在2013年被欧洲学者评为全球脑血管病研究八大进展之一,被美国评为全球神经科的十大进展之一,加拿大评为过去三年全球脑血管病的十大突破进展之一,该研究结果也在去年改变了美国的临床指南。对于怎样做好临床研

临床研究革新势在必行:以数字化转型加速药物开发创新

药物开发创新是一个周期长、高投资、高风险的过程,药物开发通常需要10年到15年的时间,投入资金会达到5到10亿美元。这个过程对于药企来说都是一个巨大的挑战,同时也是沉重的负担。各个药企现在正在积极地探索利用新的创新手段,提高临床试验、临床开发的效率,以及提高新产品上市的概率,这是所有制药企业所面临的共同的挑战。作为全球领先的生物制药服务创新企业,精鼎医药致力于在中国和全球推动实施创新,其旗下的

如何提出一个好的临床研究问题?

开展一项有影响力的临床研究,最基本的一个要求是提出一个合理的、有临床意义的研究问题。研究问题的提出应该让研究者看到一条清晰的研究路径,并产生对患者和医生有意义的证据。